EGFR and non-small cell lung carcinoma: For advanced NSCLC with EGFR mutation positive, EGFR tyrosine kinase inhibitors (EGFR‐TKIs) as first‐line treatment are recommended by oncologists.9, 10, 11, 12, 13, 14